Influenza vaccine effectiveness against influenza A subtypes in Europe: Results from the 2021–2022 I‐MOVE primary care multicentre study-Reference-Cited by-同舟云学术

Influenza vaccine effectiveness against influenza A subtypes in Europe: Results from the 2021–2022 I‐MOVE primary care multicentre study

Published:2022-11-21 Issue:1 Volume:17 Page:
ISSN:1750-2640
Container-title:Influenza and Other Respiratory Viruses
language:en
Short-container-title:Influenza Resp Viruses

Author:

Kissling Esther¹^ORCID,Pozo Francisco²³,Martínez‐Baz Iván³⁴,Buda Silke⁵,Vilcu Ana‐Maria⁶,Domegan Lisa⁷^ORCID,Mazagatos Clara³⁸^ORCID,Dijkstra Frederika⁹,Latorre‐Margalef Neus¹⁰,Kurečić Filipović Sanja¹¹,Machado Ausenda¹²^ORCID,Lazar Mihaela¹³,Casado Itziar³⁴,Dürrwald Ralf⁵^ORCID,van der Werf Sylvie¹⁴¹⁵,O'Donnell Joan⁷,Linares Dopido Juan Antonio¹⁶,Meijer Adam⁹,Riess Maximilian¹⁰,Višekruna Vučina Vesna¹¹,Rodrigues Ana Paula¹²,Mihai Maria Elena¹³,Castilla Jesús³⁴^ORCID,Goerlitz Luise⁵,Falchi Alessandra¹⁷,Connell Jeff¹⁸,Castrillejo Daniel¹⁹,Hooiveld Mariette²⁰,Carnahan Annasara¹⁰,Ilić Maja¹¹,Guiomar Raquel¹²,Ivanciuc Alina¹³,Maurel Marine¹,Omokanye Ajibola²¹,Valenciano Marta¹^ORCID,

Affiliation:

1. Epiconcept Paris France

2. National Centre for Microbiology Institute of Health Carlos III Madrid Spain

3. Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP) Madrid Spain

4. Instituto de Salud Pública de Navarra ‐ IdiSNA Pamplona Spain

5. Robert Koch Institut Berlin Germany

6. INSERM, Sorbonne Université Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136) Paris France

7. Health Service Executive‐Health Protection Surveillance Centre Dublin Ireland

8. National Centre for Epidemiology Institute of Health Carlos III Madrid Spain

9. National Institute for Public Health and the Environment (RIVM) Bilthoven The Netherlands

10. The Public Health Agency of Sweden Stockholm Sweden

11. Croatian Institute of Public Health Zagreb Croatia

12. Instituto Nacional de Saúde Dr. Ricardo Jorge Lisbon Portugal

13. “Cantacuzino” National Military Medical Institute for Research and Development Bucharest Romania

14. Unité de Génétique Moléculaire des Virus à ARN, Institut Pasteur Université Paris Cité, UMR 3569 CNRS Paris France

15. CNR virus des infections respiratoires, Institut Pasteur Paris France

16. Subdirección de Epidemiología, Dirección General de Salud Pública, Servicio Extremeño de Salud Extremadura Spain

17. Laboratoire de Virologie Université de Corse‐Inserm Corte France

18. National Virus Reference Laboratory University College Dublin Dublin Ireland

19. Servicio de Epidemiología, DGSP, Consejería de Políticas Sociales, Salud Pública y Bienestar Animal, Ciudad Autónoma de Melilla Melilla Spain

20. Nivel Utrecht The Netherlands

21. European Centre for Disease Prevention and Control Stockholm Sweden

Funder

European Centre for Disease Prevention and Control

Publisher

Wiley

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,Pulmonary and Respiratory Medicine,Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/irv.13069

Reference29 articles.

1. 2015/16 I-MOVE/I-MOVE+ multicentre case-control study in Europe: Moderate vaccine effectiveness estimates against influenza A(H1N1)pdm09 and low estimates against lineage-mismatched influenza B among children

2. I-MOVE Multi-Centre Case Control Study 2010-11: Overall and Stratified Estimates of Influenza Vaccine Effectiveness in Europe

3. Estimates of Pandemic Influenza Vaccine Effectiveness in Europe, 2009–2010: Results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) Multicentre Case-Control Study

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Influenza vaccine effectiveness in Europe: Results from the 2022–2023 VEBIS (Vaccine Effectiveness, Burden and Impact Studies) primary care multicentre study;Influenza and Other Respiratory Viruses;2024-01

2. Efectividad de la vacuna antigripal para prevenir casos graves de gripe. Temporada 2022/2023;Enfermedades Infecciosas y Microbiología Clínica;2024-01

3. End of season 2022/2023 quadrivalent influenza vaccine effectiveness in preventing influenza in primary care in Portugal;Human Vaccines & Immunotherapeutics;2023-11-15

4. Lack of neutralizing antibodies against influenza A viruses in adults during the 2022/2023 winter season – a serological study using retrospective samples collected in Hong Kong;International Journal of Infectious Diseases;2023-10

5. Clinical Features and Outcomes of the Association of Co-Infections in Children with Laboratory-Confirmed Influenza during the 2022–2023 Season: A Romanian Perspective;Viruses;2023-09-30